B+
Bull case
20%
Probability
Target price
$2.40
Analysis reference price unavailable
Analysis 2026-10-16 · RankAlpha Sentiment Codex
GANX
Gain TherapeuticsCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
Gain’s October update reported stable motor scores over 12 months in 12 evaluable Phase 1b extension participants and no new safety signal. A timely protocol submission and Phase 2 start could support revaluation, but these uncontrolled, small-study observations do not establish efficacy [#8-K-2026-10-01].
Posture
Mixed
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite.
What can break
June 30 cash was $13.1 million; the 10-Q states substantial doubt about going concern and a need for additional funding beyond Q2 2027 [#SEC-10Q-2026-08-11].
Momentum
82
Value
41
Sentiment
55
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $1.10 · Bull $2.40 · Bear $0.45Analysis 2026-10-16; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-27 • Vendor: Data Vendor v1
Scores
As of 2026-10-27 • Model: HYBRID_IC_RP
AI Memo
As of 2026-10-16 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-27
Investment thesis
As of 2026-10-27
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-27. Definitions
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $7.20
Why
Momentum82 · Δ7d -
Value41 · Δ7d -0.1
Sentiment55 · Δ7d -
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Confirming evidence
- • Sentiment remains the lead driver in the composite.
Contradictions & invalidation
- • June 30 cash was $13.1 million; the 10-Q states substantial doubt about going concern and a need for additional funding beyond Q2 2027 [#SEC-10Q-2026-08-11].
- • The October Phase 1b extension update covers only 12 evaluable participants and is open-label; apparent stabilization may not replicate in a controlled Phase 2 trial [#8-K-2026-10-01].
- • The Phase 2 start shifted from Q3 2026 to Q1 2027, while the June 10-Q reported a going-concern warning and a need for further funding beyond Q2 2027.
Catalyst clock
2026-11-30
Revised rexaceract Phase 2 protocol
Lead driver: Sentiment · See AI snapshot
Momentum
82
8% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
41
47% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-0.3
Sentiment
55
45% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade C. Momentum 82.4 / Value 40.6 / Sentiment 55.4
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-10-16. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$1.10
Analysis reference price unavailable
Analysis 2026-10-16 · RankAlpha Sentiment Codex
B-
Bear case
35%
Probability
Target price
$0.45
Analysis reference price unavailable
Analysis 2026-10-16 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-27
Fundamentals (TTM)
As of 2026-10-27
Market Cap
$51.06M
Beta
0.07
Shares Out
43.64M
P/E (TTM) · Derived
-1.9
P/S (TTM)
-
P/FCF (TTM) · Derived
-2.45
Rev YoY
-100.0%
EPS YoY
-43.1%
Gross Margin
-51.5%
Op Margin
-
Net Debt
-$20.11M
Current Ratio
4.36
As of 2026-10-27 • Updated nightlySource: Internal modelMethods & Data